For decades, there have been reports of individuals who have lived with Alzheimer's but do not have cognitive abilities disrupted. Our data consistently shows a protective protein with high levels of expression only in Alzheimer's disease (AD) resilient patients and our company will be investigating this pathway as the next therapeutic for neurodegenerative diseases.This would be the first company dedicated towards investigating these unique cases. Our research is also the first to discover a single neuroprotective protein that is strongly expressed in these individuals, and we are set to present this data at the upcoming 2020 Alzheimer's Association International Conference. This approach will likely yield a therapeutic that can apply to many other neurodegenerative diseases. Our team consists of a Neuroscientist with a PhD in Neuroscience and a Biologist with a Masters in Biology, as well as almost a decade of research experience in AD. Funds are needed to outsource significant amounts of research so that the results and interpretation of the pathway is thoroughly and unbiasedly investigated. Finally, we need funds to develop proper compounds that will activate the protein of interest in AD cases. Phase I clinical trials would then be the next step.
Ready to Ask For Funding for your company?
Post a Funding Request